Biogen

Biogen, AbbVie Withdraw MS Drug Zinbryta after Brain Disorders Spark EMA Review

Biogen and AbbVie said today they are voluntarily withdrawing Zinbryta® (daclizumab) from the market worldwide. The withdrawal came as the European Medicines Agency started an “urgent…

بیشتر بخوانید »

شرکت Biogen ممکن است تنها امیدبرای آوردن داروی آلزایمر به بازار باشد

Biogen May Be The Only Legitimate Hope For Bringing An Alzheimer’s Drug To Market Summary Biogen has set the state to potentially bring an FDA…

بیشتر بخوانید »

Biogen to Develop Alkermes’ MS Candidate ALKS 8700

Biogen will develop and commercialize Alkermes’ Phase III multiple sclerosis (MS) treatment ALKS 8700, the companies said today, through an up-to-$228 million-plus collaboration designed to…

بیشتر بخوانید »

واقعیت زیستی یک مروارید نادر در بیوتکنولوژی

Summary Bioverativ is a rare blood disease company. It has two products on the market. It generates enough free cash flow to finance the development…

بیشتر بخوانید »